/Investor DB

3E Bioventures Capital

Venture capital

Palo Alto · Seed–Series A · 5 people tracked

Also known as 3E Bioventures

Find your way into 3E Bioventures Capital

Each arrow is one introduction. Sign up to fill in the first one.

1,135 people can intro you to Melford

Ask Iris Wiggers to introduce you to Melford Yuan

You →Iris · together at ABN AMRO Bank N.V. →Melford

436 people can intro you to Frank

Ask Jamie Chen to introduce you to Frank Yan

You →Jamie · together at C4 Therapeutics →Frank

333 people can intro you to Karen

Ask Sam Okafor to introduce you to Karen Liu

You →Sam · together at Profusa →Karen

Sign up to find every way you can get introduced to 3E Bioventures Capital

  • Your email: who you already know at 3E Bioventures Capital, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the 3E Bioventures Capital team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

3E Bioventures Capital backs global leading health innovators, focusing on biotech—including new drugs, new modalities, and drug discovery platforms—and TechBio, where biology intersects with technology to disrupt established paradigms. The firm follows a science-driven, entrepreneur-friendly philosophy, collaborating closely with companies and research institutions to develop drugs and products that address significant unmet medical needs. Its name reflects its guiding principles of Expertise, Efficiency, and Execution.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Series A
HQ
Palo Alto, California, US
Leads rounds
Follows
Instruments
Equity
Founded
2015
Tracked investments
50
Unicorns
2
IPOs
4

Team · 5 people

from public directories

What they invest in

from 34 of 50 portfolio companies

Biotech ×26Healthtech ×19Medical Devices ×16Deep Tech ×13AI & Machine Learning ×10Digital Health ×6Hardware ×4Advanced Manufacturing ×2

HQs:United States×22China×5Australia×1

Who they back

founder profiles across 20 portfolio companies
30%
solo founders
6 of 20 mapped founding teams
31%
repeat founders
of 13 founders with career history
~1 yr
old at investment
median across 9 dated deals

Founding team size:solo founder×62 founders×73 founders×34+ founders×4

Where their founders studiedfrom 13 founders with education data

Yale University ×2

What their founders studiedfrom 13 founders with field-of-study data

Engineering ×6Life Sciences ×4Medicine ×4Chemistry ×2

Where their founders worked beforefrom 13 founders with career history

Children's National Health System ×2Stanford University ×2University of Michigan ×2

Investments · 50 tracked

founders shown can be your intro path

By year:2024 · 12022 · 42021 · 22020 · 42019 · 22018 · 32017 · 12015 · 118 dated

C4 Therapeuticsc4therapeutics.comin𝕏NASDAQ: CCCCDec 2015

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in

BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)

Co-investorsBain Capital Life SciencesNextech InvestRA CapitalCobro Ventures

Cytek Biosciencescytekbio.comin𝕏NASDAQ: CTKBSeries C · Oct 2020

Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets.

BiotechDeep TechHardwareHealthtechMedical DevicesBellevue, US

Wenbin Jiang, Ph.D.(CEO and Chairman of the Board)Wenbin Jiang(Executive Officer, Director)inMing Yan, Ph.D.(Chief Technology Officer)Ming Yan(Executive Officer, Director)inJiecheng Zhang(Director)Allen Poirson(Director)

Co-investorsF-Prime CapitalNorthern Light Venture CapitalRA Capital

Profusaprofusa.comin𝕏NASDAQ: PFSAAug 2018

Profusa develops injectable hydrogel biosensors and AI-driven health platforms that enable real-time measurement of body chemistry from within tissue.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSan Francisco, US

Bill Fawcett(Co-founder)Natalie Wisniewski(Executive Officer, Director)inBill McMillan(Co-Founder, CSO & Head of Research)Ben Healy(CEO)Ben Hwang(Chairman & CEO)in

BoardQianye Karen Liu(Director)

Co-investorsAsset Management CompanyAtinum Investment Co. Ltd.Sand Hill AngelsBioVentures

Twist Biosciencetwistbioscience.comin𝕏NASDAQ: TWST

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.

BiotechDeep TechSemiconductorsSouth San Francisco, US

William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily Leproust, PhD(CEO and Co-Founder of Twist)Patrick Finn(President and Chief Operating Officer)inAdam Laponis(Chief Financial Officer)in

Co-investors+ND CapitalARCH Venture PartnersAsset Management CompanyATEL VenturesBay City CapitalBlack Opal Ventures+10 more

Arnatar Therapeuticsarnatar.comin𝕏✓ verified

Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics.

AI & Machine LearningBiotechDeep Tech

Dr. Xuehai Liang(Founder)Dr. Yanfeng Wang(Founder & Chief Operating Officer)

Co-investorsF-Prime CapitalApricot CapitalEight Roads VenturesGaorong VenturesLegend StarNew Alliance Capital

Dermaliqdermaliq.com✓ verified

Dermaliq Therapeutics is a specialty pharmaceutical company developing topical dermatology therapies and medical skin care products based on its proprietary hyliQ drug-delivery platform, with a lead pipeline focused on hair loss conditions such as androgenetic alopecia and alopecia areata.

BiotechHealthtechWilmington, US

Oliver Schlüter(CFO & Co-Founder)Betsy Hughes-Formella(CSO & Co-Founder / R&D Consultant)Christian Roesky(CEO & President)

Pronovotxpronovotx.com✓ verified

ProNovo Therapeutics is a biotechnology company developing precision small-molecule therapeutics for neuropsychiatric disorders, including Major Depressive Disorder and Schizophrenia.

BiotechHealthtechMental Health

Guang Chen(Founder, Board Director & Chief Scientific Officer)inXiaohu Deng(Co-Founder & CEO)inScott Thompson(Co-Founder & Chair of Scientific Advisory Board)in

Co-investorsGaorong Ventures

Alebundalebund.cominSep 2021 · $54.5M

An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.

BiotechDigital HealthHealthtechMedical DevicesShanghai, CN

Co-investorsLAVLilly Asia VenturesQuan Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital

Apexigenapexigen.comAug 2018 · $73M

BiotechSan Carlos, US

Xiaodong Yang(President, CEO and Secretary)inOvid Trifan(Executive Officer)Amy Wong(Executive Officer)Francis Sarena(Chief Operating Officer)Frank Hsu(Chief Medical Officer)William Duke, Jr.(Chief Financial Officer)

Co-investorsEFung CapitalShangBay Capital LLCDecheng CapitalSv Tech Ventures, Inc.Virtus Inspire Ventures

Aravivearavive.comOct 2022

BiotechHouston, US

Amato Giaccia(Director)Rudy Howard(Chief Financial Officer)Robert B. Geller(Chief Medical Officer)inGail McIntyre(Chief Executive Officer)Leonard Scott Dove(Chief Operating Officer)Joshua Brumm(Executive Officer)

Co-investorsAdvent Life SciencesEshelman Ventures, LLC

Avirmaxavirmax.comin𝕏Nov 2019

Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases.

BiotechDeep TechMedical DevicesHayward, US

Haifeng Chen(Director and Treasurer of the Issuer)inShengjiang Liu(Executive Officer, Director)

BoardYu Fang(Director of the Issuer)Qianye Karen Liu(Director of the Issuer)Nancy Chang(Director of the Issuer)

Co-investorsBioVentures

Biocytogenbiocytogen.com.cnin𝕏Apr 2018

Biocytogen (HKEX: 02315) is a global biotechnology company that uses genetically engineered mouse models and its RenMice/RenMab/RenNano fully human antibody platforms to develop therapeutic antibody drugs.

BiotechDeep TechHealthtechBeijing, CN

Yuelei Shen(Founder)in

Co-investorsCowin Capital GroupOriza HoldingsSDIC Venture Capital

Cognition Therapeuticscogrx.comin𝕏

Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers.

BiotechHealthtechPittsburgh, US

Susan Catalano(Executive Officer, Director)inSusan Catalano, Ph.D.(Co-founder)Lisa Ricciardi(Chief Executive Officer)inHarold Safferstein(Executive Officer, Director)

BoardNada Jain(Director)Franz Hefti(Director)

Co-investorsArieal Southeast Angel PartnersAtlanta Technology AngelsCowtown AngelsDolby Family VenturesGolden SeedsHouston Angel Network+1 more

Cullgencullgen.comin𝕏Series B · Feb 2021 · $50M

Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach.

BiotechDeep TechHealthtechMedical Devices

Ying Luo(CEO)in

Co-investorsHongShan Capital Group

Dewpointdewpointinnov.cominFeb 2022

Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.

CleantechClimate TechDeep TechNew Materials

Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in

Co-investorsImpact Ventures Management Pty LtdPacific ChannelARCH Venture PartnersEcoR1 CapitalGeneral CatalystLeaps by Bayer+3 more

Dewpoint Therapeuticsdewpointx.comin𝕏Feb 2022

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)

Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation Endeavors+6 more

Eaglenoseaglenos.com

Eaglenos develops smart healthcare technologies, focusing on precision testing and personalized health management.

Digital HealthHealthtechMedical DevicesNanjing, CN

EpimAb Biotherapeuticsepimab.com

Epimab Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of bispecific antibodies using proprietary technology platforms including FIT-Ig® and MAT-Fab.

BiotechHealthtechMedical DevicesShanghai, CN

Wu Chenbing(Founder/Expert)

Co-investorsDecheng CapitalShangBay Capital LLCTCG LabsSherpa Healthcare Partners

Fa Infa-in.com

FA International provides technology and business development advisory services for industrial and medical device companies, helping them evaluate pre- and post-investment opportunities and technology risks to optimize returns and develop growth strategies.

Advanced ManufacturingDeep TechEnterprise SoftwareHardwareMedical Devices

Gb Scientificgb-scientific.com

Galaxy Brain Scientific develops personalized brain mapping and neuromodulation technologies for research and clinical applications across neurological conditions.

AI & Machine LearningBiotechDeep TechMedical Devices

Genotixbiogenotixbio.comin

Genotix Bio develops the DaVinci, a compact nanoarray analyzer that detects proteins and nucleic acids at single-molecule resolution for research applications.

BiotechDeep TechDigital HealthHealthtechMedical DevicesSan Francisco, US

Dr. Yong Chen(Co-founder)George Brittain(Co-founder)inPan MaoinPhilippe Goix(CEO and Board Member)in

Lipidiopharmalipidiopharma.comNov 2019

Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit.

BiotechHealthtechSan Diego, US

James Mackay(Co-Founder)David Bullough(Director)Daniel Petree(Director)J. Gordon Foulkes(Executive Officer, Director)

LumiTheralumithera.com

LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD).

BiotechHealthtechMedical DevicesPoulsbo, US

Tracy Puckett(Executive Officer)Clark Tedford(Executive Officer, Director)inScott Bradley(Executive Officer)inDuane Morrison(Executive Officer)inCindy Croissant(Executive Officer)Ryan Montecucco(Executive Officer)

Co-investorsEFung CapitalKeiretsu ForumLife Sciences Greenhouse InvestmentsImagine VenturesKeiretsu Capital

Mediaspacemediaspace.coin𝕏

Mediaspace is a digital agency that designs and builds custom Squarespace websites and provides SEO, digital marketing strategy, and digital advertising services.

AdTechAdvanced ManufacturingAI & Machine LearningData & InfrastructureDigital HealthEnterprise SoftwareHardwareHealthtechMarketing TechMedical DevicesSemiconductorsAtlanta, US

John G. Edwards(Executive Officer, Director)John Jacobi(Executive Officer)Sri Peruvemba(Executive Officer)Francois Jeanneau(Executive Officer, Director)Linda Ara(Executive Officer)Michael Vestel(Executive Officer)

Co-investorsKeiretsu ForumLife Sciences Greenhouse InvestmentsToba CapitalVivo Capital

Myrobalan Therapeuticsmyrotx.cominSeries A · Jan 2024 · $24M

Myrobalan Therapeutics is a pre-clinical biotech company developing small molecule therapies targeting microglia and oligodendrocytes to address neurodegeneration and demyelinating disorders.

AI & Machine LearningBiotechDeep TechMedical DevicesBoston, US

Jing Wang, PhD(Co-Founder & CEO)Guoping Feng, PhD(Scientific Co-Founder)Zhigang He(Scientific Co-founder)Guoping Feng(Scientific Co-founder)Minmin Yang(Director)Jing Yu Wang(Executive Officer, Director)

Neural Galaxyneuralgalaxy.com

Company from Harvard Medical School and MIT McGovern Institute aiming to solve brain disorders.

Co-investorsBRC InnovationFoothill Ventures

OncoC4oncoc4.cominDec 2020

OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders.

BiotechHealthtechRockville, US

Yang Liu(Co-founder)inPan Zheng(Co-founder)inMartin Devenport(Executive Officer)Michael Flaschen(Director)

Co-investorsHM Venture Partners

OncoImmuneoncoimmune.comJan 2017 · $56M

First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.

BiotechRockville, US

Pan Zheng(Executive Officer)Yang Liu(Executive Officer, Director)Martin Devenport(Executive Officer)

BoardMiao Hong(Director)Karen Liu(Director)inKun-Liang Guan(Director)

Co-investorsHM Venture Partners

Quadrigabiosciencesquadrigabiosciences.com

Quadriga BioSciences is an oncology startup developing targeted small molecule chemotherapeutics for cancer treatment, with a focus on central nervous system malignancies and immune-mediated disorders.

BiotechHealthtechMedical Devices

Gordon Ringold(CEO)Bernd Jandeleit(Co-Founder)Wolf-Nicolas Fischer(Co-Founder)Kerry J. Koller(Co-Founder)

Rapafusynrapafusyn.comin

Rapafusyn develops molecular glue therapeutics using its RapaGlue platform of non-degrading macrocyclic compounds designed to modulate hard-to-drug intracellular and transmembrane protein targets.

AI & Machine LearningBiotechDeep TechBaltimore, US

Jun O. Liu(Founder)

Co-investorsBioTrack Capital

Shantonpharmashantonpharma.comin

Shanton Pharma is a clinical-stage biotech company developing drugs for gout, hyperuricemia, and pruritus.

BiotechHealthtech

Smartlenssmartlens.healthin

Smartlens develops wearable microfluidic devices and AI-powered platforms for remote monitoring and diagnosis of anterior segment eye diseases, particularly glaucoma.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Savas Komban(Founder)in

Co-investorsAmbit Health VenturesDevice of Tomorrow CapitalStanford University

Subtlesubtle.coin𝕏Nov 2020 · $12.2M

Subtle Computing (legally Skywalk, Inc.) makes wireless earbuds sold directly at subtle.co and through authorized resellers, along with a companion mobile app.

AI & Machine LearningConsumerDirect to ConsumerHardware

Tyler Chen(Founder)inDavid Harrison(Founder)Jackie Yang(Founder)Savannah Cofer(Founder)

Co-investorsAbstract VenturesEntrada VenturesInception Studio CapitalSLVCBaidu VenturesBessemer Venture Partners+10 more

Subtle Medicalsubtlemedical.cominNov 2020

Subtle Medical develops deep learning software for medical imaging that enables faster and safer image acquisition on existing scanners for healthcare providers and imaging centers.

AI & Machine LearningHealthtechMedical Devices

Greg Zaharchuk(Co-founder, MD, Ph.D., Neuroradiologist and Professor at Stanford)inEnhao Gong(Co-founder, Ph.D., Deep Learning Scientist)in

Co-investorsAtinum Investment Co. Ltd.Bessemer Venture PartnersBreyer CapitalDCVC (Data Collective)Foothill VenturesFusion+9 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

ArnatarCytekEluminexEluminexbioGenotixLarkspurLipidioLysowayLysoway TherapeuticsMyro TherapeuticsNanoInsights-TechProNovoRegenacy PharmaceuticalsRetex PharmaceuticalsSHANTONTwist

Exits · 4

4 IPOs

C4 TherapeuticsNASDAQ: CCCCCytek BiosciencesNASDAQ: CTKBProfusaNASDAQ: PFSATwist BioscienceNASDAQ: TWST

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has 3E Bioventures Capital made?
3E Bioventures Capital has 50 tracked investments, 4 of which have exited.
What stage does 3E Bioventures Capital invest at?
3E Bioventures Capital invests at the Seed, Series A stages.
What sectors does 3E Bioventures Capital focus on?
3E Bioventures Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices.
Where is 3E Bioventures Capital located?
3E Bioventures Capital is headquartered in Palo Alto, US.
Does 3E Bioventures Capital lead rounds?
3E Bioventures Capital typically participates in rounds rather than leading them.
Who does 3E Bioventures Capital co-invest with?
3E Bioventures Capital most often shares deals with ARCH Venture Partners, Asset Management Company, F-Prime Capital, among 50 tracked co-investors.

Similar investors

Featured in lists